Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.
Rapid, robust, and affordable genetic testing for patients with ovarian cancer that allows a much larger portion of patients to benefit from personalized cancer management and their relatives to benefit from preventive strategies can be achieved.
Risk of ovarian cancer is higher in African American women with lower socioeconomic status, the opposite of trends seen in breast cancer.
Despite confirmation of a link between routine Pap smear screening and a lower risk of developing cervical cancer in women older than 65 years, most US health guidelines discourage older women from undergoing routine Pap smears unless they have pre-existing risk factors.
Prophylactic Gynecologic Resections Increase Risk for Aggressive Uterine Cancer in BRCA Gene Mutation CarriersJuly 19, 2016
Women who carry the BRCA1 mutation are at increased risk for serous/serous-like endometrial carcinoma after risk-reducing salpingo-oophorectomy. Yet uncertainty exists over the need to perform a full hysterectomy in these women.
Fewer cervical cell anomalies were present on cervical cancer screens of young women in Canada who received the HPV vaccine through a school-based program.
Adjuvant chemotherapy administered during and after radiotherapy is feasible for the treatment of patients with high-risk endometrial cancer despite an increased risk of toxicities compared with radiotherapy alone.
A newly created tumor-specific fluorescent molecule combined with an imaging system guided surgeons to removing additional tumors not palpable or visible without fluorescence in patients with ovarian cancer.
Immunotherapy for advanced ovarian cancer more effectively treats tumors when administered immediately after chemotherapy. Sequential chemoimmunotherapy could improve disease control in stage IIIC/IV tubo-ovarian HGSC.
The number of patients older than 75 years who do not undergo surgery is increasing, especially among those with stage III or IV ovarian cancer. Approximately 50% do not undergo surgery and 25% receive no treatment at all.
Overall risk of developing ovarian cancer may be higher for women with certain types of human leukocyte antigen (HLA), which could underlie differences in their response to immunotherapy.
Cell Changes in Fallopian Tubes of BRCA Mutation Carriers May Lead to Strategies for Preventing Ovarian CancerJune 13, 2016
Recognition of early changes in the Fallopian tube cells of BRCA gene mutation carriers may be key to new strategies for preventing ovarian cancer that could also reduce the need for invasive surgery.
ASCO has published its first clinical practice guideline on invasive cervical cancer, and the guidelines are the first to offer treatment recommendations tailored to resource availability.
A new perspective on chemotherapy resistance in ovarian cancer may be a step toward overcoming that resistance. Fibroblasts block chemotherapy, leading to chemotherapy resistance; however, immune system T cells can reverse that resistance.
No Clinical Benefit to Expanding Gene Panel Beyond Ovarian and Breast Cancer Genes in High-risk WomenMay 20, 2016
Expanding a panel of tested genes beyond the known breast and ovarian cancer-specific genes in patients with breast and ovarian cancer did not confer any clinical benefit.
Excess abdominal fat in overweight and obese women could interfere with detection of early symptoms of ovarian cancer, and this may contribute to the higher risk of death from ovarian cancer in African American women compared with white women.
In patients with cervical cancer who do not have enlarged lymph nodes, SPECT-MRI imaging of their sentinel lymph nodes (SLNs) could assess whether metastases are present.
Nurse-based telephone follow-up was as effective as traditional hospital based follow-up for for stage I endometrial cancer.
Risk-reducing mastectomy (RRM) can increase life expectancy and be cost effective in women up to age 60 years with ovarian cancer as carriers of a BRCA mutation.
In a small group of women with mismatch repair (MMR) deficiency endometrial uterine cancer, survival was increased by pembrolizumab.
Hormone Replacement Therapy Improves Bone Mineral Loss After Salpingo-oophorectomy for Ovarian CancerApril 11, 2016
In patients who undergo risk-reducing salpingo-oophorectomy, BMD screenings are underutilized in spite of the prevalence of bone mineral loss in this population. Hormone replacement therapy can address BMD loss in these women.
Progression-free and Overall Survival Better With Mutations Affecting DNA Repair Genes in Ovarian CancerApril 08, 2016
Women with advanced ovarian cancer who had mutations affecting DNA repair genes had longer progression-free and overall survival than women without the mutations.
Adding farletuzumab to carboplatin and a taxane failed to improve progression-free survival in patients with platinum-sensitive ovarian cancer.
A methylation signature was identified in 5 types of cancer, and it likely occurs in more. These findings may aid in developing a blood test to diagnose cancer at early stages, when it is most treatable.
Incidence of Undetected Cancer in Patients Undergoing Gynecologic Surgery for a Benign Condition Higher Than EstimatedDecember 04, 2015
Researchers in Massachusetts sought to determine how frequently cancer is diagnosed in women after undergoing gynecologic surgery for a problem believed to be benign.
Venlafaxine has a significant clinical activity against taxane-oxaliplatin-induced acute neurosensory toxicity in patients with cancer.
Survival for women with advanced ovarian cancer may be negatively impacted when chemotherapy is initiated more than 25 days after surgery.
Women with epithelial ovarian cancer, the most common type, can safely take hormone replacement therapy (HRT).
Oral contraceptives protect against endometrial cancer, and the protective benefit lasts for many years after women stop taking the pills.
Use of oral contraceptives, even short-term, offers significant long-term protection against endometrial cancer and the protective effect seems to linger for decades after contraceptive is discontinued.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
- Replacing Neoadjuvant CRT with Multiagent Chemo Not Recommended for Rectal Cancer
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|